Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease

Molecular Immunology

Volumn 58, Issue 2, 2014, Pages 182-186

  Achberger, Susan ^a   Aldrich, Wayne ^a   Tubbs, Raymond ^b   Crabb, John W ^b   Singh, Arun D ^b   Triozzi, Pierre L ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biomarkers; Immune response; MicroRNA; Uveal melanoma

Indexed keywords

CD15 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; MICRORNA; MICRORNA 125B; MICRORNA 146A; MICRORNA 181A; MICRORNA 20A; MICRORNA 223; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE METASTASIS; CANCER IMMUNOLOGY; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMAGNETIC SEPARATION; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS; MIDDLE AGED; NATURAL KILLER CELL; NATURAL KILLER T CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE; UVEA MELANOMA;

BIOMARKERS; IMMUNE RESPONSE; MICRORNA; UVEAL MELANOMA;

AGED; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MELANOMA; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; UVEAL NEOPLASMS;

EID: 84891095490     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.11.018     Document Type: Article

References (39)

1. Blom D.J., Luyten G.P., Mooy C., Kerkvliet S., Zwinderman A.H., Jager M.J. Human leukocyte antigen class I expression: marker of poor prognosis in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 1997, 38:1865-1872.
2. Bricard G., Cesson V., Devevre E., Bouzourene H., Barbey C., Rufer N., Im J.S., Alves P.M., Martinet O., Halkic N., Cerottini J.C., Romero P., Porcelli S.A., Macdonald H.R., Speiser D.E. Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J. Immunol. 2009, 182:5140-5151.
3. Cubillos-Ruiz J.R., Baird J.R., Tesone A.J., Rutkowski M.R., Scarlett U.K., Camposeco-Jacobs A.L., Anadon-Arnillas J., Harwood N.M., Korc M., Fiering S.N., Sempere L.F., Conejo-Garcia J.R. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 2012, 72:1683-1693.
4. Dithmar S., Rusciano D., Lynn M.J., Lawson D.H., Armstrong C.A., Grossniklaus H.E. Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch. Ophthalmol. 2000, 118:1085-1089.
5. Dooley J., Linterman M.A., Liston A. MicroRNA regulation of T-cell development. Immunol. Rev. 2013, 253:53-64.
6. Dubovsky J.A., Villagra A., Powers J.J., Wang H.W., Pinilla-Ibarz J., Sotomayor E.M. Circumventing immune tolerance through epigenetic modification. Curr. Pharm. Des. 2010, 16:268-276.
7. Eyles J., Puaux A.L., Wang X., Toh B., Prakash C., Hong M., Tan T.G., Zheng L., Ong L.C., Jin Y., Kato M., Prévost-Blondel A., Chow P., Yang H., Abastado J.P. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 2010, 120:2030-2039.
8. Ferracin M., Veronese A., Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev. Mol. Diagn. 2010, 10:297-308.
9. Fu T., He Q., Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 2011, 71:5445-5454.
10. Gros A., Turcotte S., Wunderlich J.R., Ahmadzadeh M., Dudley M.E., Rosenberg S.A. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin. Cancer Res. 2012, 18:5212-5223.
11. Haynie G.D., Shen T.T., Gragoudas E.S., Young L.H. Flow cytometry analysis of peripheral blood lymphocytes in patients with choroidal melanoma. Am. J. Ophthalmol. 1997, 124:357-361.
12. Henao-Mejia J., Williams A., Goff L.A., Staron M., Licona-Limón P., Kaech S.M., Nakayama M., Rinn J.L., Flavell R.A. The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity 2013, 38:984-997.
13. Hezova R., Slaby O., Faltejskova P., Mikulkova Z., Buresova I., Raja K.R., Hodek J., Ovesna J., Michalek J. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell. Immunol. 2010, 260:70-74.
14. + regulatory T cells in human thymus and periphery. Immunity 2008, 28:870-880.
15. Jackson A., Linsley P.S. The therapeutic potential of microRNA modulation. Discov. Med. 2010, 9:311-318.
16. Kohlhaas S., Garden O.A., Scudamore C., Turner M., Okkenhaug K., Vigorito E. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J. Immunol. 2009, 182:2578-2582.
17. Kujala E., Makitie T., Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2003, 44:4651-4659.
18. Leong J.W., Sullivan R.P., Fehniger T.A. Natural killer cell regulation by microRNAs in health and disease. J. Biomed. Biotechnol. 2012, 2012:632329.
19. Li Q.J., Chau J., Ebert P.J., Sylvester G., Min H., Liu G., Braich R., Manoharan M., Soutschek J., Skare P., Klein L.O., Davis M.M., Chen C.Z. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007, 129:147-161.
20. Li K., Seo K.H., Gao T., Zheng Q., Qi R.Q., Wang H., Weiland M., Dong Z., Mi Q.S., Zhou L. Invariant NKT cell development and function in microRNA-223 knockout mice. Int. Immunopharmacol. 2011, 11:561-568.
21. + myeloid-derived suppressor cells from bone marrow cells. Int. J. Cancer 2011, 129:2662-2673.
22. + T cells of multiple sclerosis relapsing patients. Int. J. Neurosci. 2012, 122:466-471.
23. Ly L.V., Baghat A., Versluis M., Jordanova E.S., Luyten G.P., van Rooijen N., van Hall T., van der Velden P.A., Jager M.J. In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J. Immunol. 2010, 185:3481-3488.
24. Maat W., van der Slik A.R., Verhoeven D.H., Alizadeh B.Z., Ly L.V., Verduijn W., Luyten G.P., Mulder A., van Hall T., Koning F., Jager M.J., van Bergen J. Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients. Invest. Ophthalmol. Vis. Sci. 2009, 50:2888-2895.
25. Manyś-Kubacka K., Kostrzewa A., Sobieska M., Samborski W. Alterations of lymphocyte subpopulations in choroidal melanoma patients undergoing surgery. Rocz. Akad. Med. Bialymst. 2005, 50:289-292.
26. McKenna K.C., Beatty K.M., Bilonick R.A., Schoenfield L., Lathrop K.L., Singh A.D. Activated CD11b+ CD15+ granulocytes increase in the blood of patients with uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2009, 50:4295-4303.
27. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
28. Mougiakakos D., Johansson C.C., Trocme E., All-Ericsson C., Economou M.A., Larsson O., Seregard S., Kiessling R. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer 2010, 116:2224-2233.
29. Ng S.B., Yan J., Huang G., Selvarajan V., Tay J.L., Lin B., Bi C., Tan J., Kwong Y.L., Shimizu N., Aozasa K., Chng W.J. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 2011, 118:4919-4929.
30. Niederkorn J.Y. Immune escape mechanisms of intraocular tumors. Prog. Retin. Eye Res. 2009, 28:329-347.
31. Pan W., Zhu S., Yuan M., Cui H., Wang L., Luo X., Li J., Zhou H., Tang Y., Shen N. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4 T cells by directly and indirectly targeting DNA methyltransferase 1. J. Immunol. 2010, 184:6773-6781.
32. Singh A.D., Turell M.E., Topham A.K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011, 11:1881-1885.
33. Singh A.D., Aronow M.E., Sun Y., Bebek G., Saunthararajah Y., Schoenfield L.R., Biscotti C.V., Tubbs R.R., Triozzi P.L., Eng C. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest. Ophthalmol. Vis. Sci. 2012, 53:3331-3339.
34. Staibano S., Mascolo M., Tranfa F., Salvatore G., Mignogna C., Bufo P., Nugnes L., Bonavolontà G., De Rosa G. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior. Int. J. Immunopathol. Pharmacol. 2006, 19:171-179.
35. Torres V., Triozzi P., Eng C., Tubbs R., Schoenfiled L., Crabb J.W., Saunthararajah Y., Singh A.D. Circulating tumor cells in uveal melanoma. Future Oncol. 2011, 7:101-109.
36. Triozzi P.L., Elson P., Aldrich W., Achberger A., Tubbs R., Biscotti C.V., Singh A.D. Elevated blood beta-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma. Melanoma Res. 2013, 23:1-7.
37. Tsitsiou E., Lindsay M.A. microRNAs and the immune response. Curr. Opin. Pharmacol. 2009, 9:514-520.
38. Tsitsiou E., Williams A.E., Moschos S.A., Patel K., Rossios C., Jiang X., Adams O.D., Macedo P., Booton R., Gibeon D., Chung K.F., Lindsay M.A. Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma. J. Allergy Clin. Immunol. 2012, 129:95-103.
39. Yang W., Li H., Mayhew E., Mellon J., Chen P.W., Niederkorn J.Y. NKT cell exacerbation of liver metastases arising from melanomas transplanted into either the eyes or spleens of mice. Invest. Ophthalmol. Vis. Sci. 2011, 52:3094-3102.